# A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

> **NCT03798106** · PHASE2 · COMPLETED · sponsor: **Yonsei University** · enrollment: 46 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Durvalumab, pazopanib

## Key facts

- **NCT ID:** NCT03798106
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-10
- **Primary completion:** 2022-08-10
- **Final completion:** 2022-08-10
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03798106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03798106, "A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03798106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*